Blog

Giuseppe Banna: Enjoyed being part of the EAU 2025 Symposium

Giuseppe Banna/LinkedIn

Mar 24, 2025, 09:15

Giuseppe Banna: Enjoyed being part of the EAU 2025 Symposium

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:

“I truly enjoyed being part of this insightful symposium with Verane Achard, Teresa Lopez, and Alberto Briganti at EAU25, discussing relugolix, an LHRH antagonist with lower cardiovascular risk and rapid, profound castration and PSA decline.

It makes a valuable option in metastatic hormone-sensitive prostate cancer (mHSPC), particularly in the context of treatment de-escalation strategies. – Giuseppe Banna

Great discussions and perspectives – looking forward to continuing the conversation!”

Giuseppe Banna

Alberto Briganti cancer cardiovascular risk EAU25 Giuseppe Banna Metastatic Hormone-sensitive Prostate Cancer OncoDaily Oncology prostate cancer Teresa Lopez Verane Achard

Does Vaping Cause Lung Cancer? Myths and Facts

James Van Der Beek: Battle with Colorectal Cancer and Marriage Challenges During Treatment

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care

OncoDaily Launches New Social Channel on Telegram – @OncoDaily